EXTENDED FIELD RADIATION AND CISPLATIN FOR STAGE IIB AND IIIB CERVICAL-CARCINOMA

Objective. The aim of this study was to investigate local regional con trol, survival, and morbidity in patients with FIGO IIB and IIIB squam ous cell carcinoma of the cervix treated with primary extended field ( prophylactic paraaoratic radiation) radiation and weekly cisplatin. Me thods. Sixty-seven patients (44 IIB and 23 IIIB) with carcinoma of the cervix received cisplatin at 1 mg/kg (up to 60 mg) weekly and extende d field radiation therapy including the paraaortic nodes and brachythe rapy. Results. After the scheduled therapy 94.1% of the patients were complete responders. Seventy-five percent are alive a without evidence of disease with a mean follow-up of 47.5 months. Conclusion. This stu dy confirms the ability to give concomitant weekly cisplatin and proph ylactic paraaortic radiation with minimal morbidity. The encouraging K aplan-Meier survival of 75% and only eight pelvic failures warrants fu rther investigation. (C) 1997 Academic Press.